Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Common Equity (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Common Equity for 7 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 66.97% to $2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 66.97% decrease, with the full-year FY2024 number at $8.0 million, up 1835.28% from a year prior.
  • Common Equity was $2.5 million for Q3 2025 at Vivos Therapeutics, down from $4.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $36.5 million in Q2 2021 to a low of $46000.0 in Q3 2023.
  • A 5-year average of $10.7 million and a median of $7.0 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 99.53% in 2023, then soared 16563.04% in 2024.
  • Vivos Therapeutics' Common Equity stood at $25.5 million in 2021, then crashed by 81.2% to $4.8 million in 2022, then crashed by 91.44% to $411000.0 in 2023, then skyrocketed by 1835.28% to $8.0 million in 2024, then plummeted by 68.17% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Common Equity are $2.5 million (Q3 2025), $4.6 million (Q2 2025), and $4.4 million (Q1 2025).